You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

210 Results
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    lomustine
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Lomustine for Recurrent Glioblastoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
lomustine,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
gemcitabine,
CISplatin,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2020
Document
Apr 2020
Cette page s’adresse aux personnes ayant récemment reçu un diagnostic de leucémie aiguë lymphoblastique (LAL)
Statistical Reports
Document
May 2020
Document
Jun 2020
Drug
Other Name(s): Lorbrena®
Quick Link(s): Drug Monograph, Patient Info Sheet
Feb 2025
Document
Sep 2020
Trouvez des liens vers des pages d’information sur les soins de cancérologie offerts en Ontario pendant la pandémie de COVID-19.

Pages